Osteopetrosis and Pagets
Osteopetrosis (Marble Bone Disease)
Osteopetrosis is characterized by increased bone sclerosis due to deficient osteoclast activity, leading to brittle yet sclerotic bones.
Types of Osteopetrosis
- Autosomal Recessive (Infantile Malignant)
- Severe form, often leading to death in infancy.
- Autosomal Dominant (Benign)
- Also known as Albers-Schonberg disease.
- Typically diagnosed incidentally after a fracture or X-ray.
Diagnosis
- Diagnosis of the benign type is usually incidental, especially after fractures or cranial X-rays.
- Additional findings may include:
- Anemia
- Cranial nerve palsies, such as hearing loss.
Histology
- Osteoclasts lack the typical ruffled border.
- Presence of calcified bars within mature trabeculae.
X-ray Features
- Loss of medullary cavities due to sclerosis.
- Bone within a bone appearance.
- Symmetric, uniform sclerosis.
Treatment
- Interferon
- Bone marrow transplant for the malignant infantile type.
Paget’s Disease of Bone
Paget’s disease is a metabolic disorder involving overactivity of osteoclasts and osteoblasts, leading to abnormal bone formation.
Epidemiology
- Men are slightly more affected.
- Common in regions such as the USA and UK.
- Increases with age: affects 3% of people over 40 years and 10% over 80 years.
Types
- Monostotic: Affects one bone (20% of cases).
- Polystotic: Affects multiple bones (80% of cases).
Causes
- Viral-induced: Linked to paramyxovirus, respiratory syncytial virus, and canine distemper virus.
- Genetic: Some hereditary predisposition.
Pathophysiology
- Initial problem lies in osteoclasts, which increase in size and number, becoming overactive.
- Osteoblasts respond by increasing activity, leading to accelerated but disorganized bone formation.
Phases of Paget’s Disease
- Lytic Phase: Dominated by osteoclast activity, causing bone lysis.
- Active Phase: Osteoblast activity increases, resulting in mixed sclerotic and lytic areas.
- Burnt-out Phase: Residual effects of the active stage; the bone appears coarse with a mosaic-like trabeculae.
Clinical Presentation
- Asymptomatic in 95% of cases, with many diagnoses being incidental.
- Fractures: Slower healing fractures, requiring fixation.
- Arthritis: Commonly affects the hip and knee, leading to protrusio acetabuli.
- Bone Pain: Uncommon but can indicate high turnover or malignancy (e.g., osteosarcoma).
- Nerve Compression: Spinal stenosis or hearing loss.
- Deformities: Bowing of long bones (e.g., Sabre tibia).
- Cardiac Failure: Due to high vascularity of the bone.
- Gout: Due to increased protein metabolism.
- Malignant Transformation: Increased risk of osteosarcoma.
X-ray Features
- Widened bones: A compensatory response.
- Pathologic/stress fractures.
- Blade/flame sign: Seen in the lytic stage.
- Mosaic-like pattern: Mixed sclerotic and lytic areas.
- Deformities and secondary osteoarthritis.
- Hip protrusio: Protrusion of the acetabulum into the pelvic cavity.
Laboratory Findings
- Normal calcium levels.
- Elevated alkaline phosphatase: Reflects increased osteoblast activity.
- Elevated acid phosphatase: Reflects increased osteoclast activity.
- Urinary collagen peptides and hydroxyproline: Indicate high collagen turnover.
Histology
- Mosaic-like bone marrow.
- Scanty cells.
Bone Scan
- Shows high uptake in areas of active disease.
Treatment Options
Treatment is indicated for: - Pathologic fractures - Bone pain - Nerve/spinal compression - Osteoarthritis - Cardiac failure due to high output - Gout - Pre-surgery to reduce bleeding risk.
Medical Treatment
- Bisphosphonates: Inhibits osteoclast overactivity.
- Calcitonin: Less commonly used due to side effects.
Surgical Treatment
- Fracture fixation is preferred due to long healing times.
- Arthroplasty: For joint involvement.
- Nerve decompression: In cases of nerve compression.
- Malignant transformation treatment: For osteosarcoma or other sarcomas.
Malignant Transformation
- 30x increased risk of osteosarcoma, especially in long-standing polystotic disease.
- May also develop fibrosarcoma or chondrosarcoma.
- Prognosis: 50% survival rate for osteosarcoma.